Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumorsSALTZ, L. B; SPRIGGS, D; SEMPLE, D et al.Journal of clinical oncology. 1998, Vol 16, Num 12, pp 3858-3865, issn 0732-183XArticle

Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactionsSLATTER, J. G; SU, P; SAMS, J. P et al.Drug metabolism and disposition. 1997, Vol 25, Num 10, pp 1157-1164, issn 0090-9556Article

Erlotinib in African Americans With Advanced Non―Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic AnalysesPHELPS, M. A; STINCHCOMBE, T. E; AIMIUWU, J et al.Clinical pharmacology and therapeutics. 2014, Vol 96, Num 2, pp 182-191, issn 0009-9236, 10 p.Article

Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patientsSCHAAF, L. J; DOBBS, B. R; EDWARDS, I. R et al.European journal of clinical pharmacology. 1987, Vol 32, Num 4, pp 411-418, issn 0031-6970Article

Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancyPITOT, H. C; GOLDBERG, R. M; SCHAAF, L. J et al.Clinical cancer research. 2000, Vol 6, Num 6, pp 2239-2244, issn 1078-0432Article

Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumorsDRENGLER, R. L; KUHN, J. G; ELFRING, G. L et al.Journal of clinical oncology. 1999, Vol 17, Num 2, pp 685-696, issn 0732-183XArticle

Evaluation of the pharmacokinetic interaction between cimetidine or famotidine and cyclosporine in healthy menSHAEFER, M. S; ROSSI, S. J; MCGUIRE, T. R et al.The Annals of pharmacotherapy. 1995, Vol 29, Num 11, pp 1088-1091, issn 1060-0280Article

Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignanciesXU, Y; KOLESAR, J. M; SCHAAF, L. J et al.Cancer chemotherapy and pharmacology. 2009, Vol 63, Num 6, pp 1073-1082, issn 0344-5704, 10 p.Article

Irinotecan therapy in adults with recurrent or progressive malignant gliomaFRIEDMAN, H. S; PETROS, W. P; CLOUGHSEY, T et al.Journal of clinical oncology. 1999, Vol 17, Num 5, pp 1516-1525, issn 0732-183XArticle

Effect of an enteral nutrient formula on sustained-release theophylline absorptionBHARGAVA, V. O; SCHAAF, L. J; BERLINGER, W. G et al.Therapeutic drug monitoring. 1989, Vol 11, Num 5, pp 515-519, issn 0163-4356Article

The pharmacokinetics of doxifluridine and 5-fluorouracil after single intravenous infusions of doxifluridine to patients with colorectal cancerSCHAAF, L. J; DOBBS, B. R; EDWARDS, I. R et al.European journal of clinical pharmacology. 1988, Vol 34, Num 5, pp 439-443, issn 0031-6970Article

Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeksROTHENBERG, M. L; KUHN, J. G; ELFRING, G. L et al.Annals of oncology. 2001, Vol 12, Num 11, pp 1631-1641, issn 0923-7534Article

Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [¹⁴C]CPT-11 in cancer patientsSLATTER, J. G; SCHAAF, L. J; MILLER, L. L et al.Drug metabolism and disposition. 2000, Vol 28, Num 4, pp 423-433, issn 0090-9556Article

A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I studyVAN TELLINGEN, O; PUNT, C. J. A; AWADA, A et al.Cancer chemotherapy and pharmacology. 1998, Vol 41, Num 5, pp 377-384, issn 0344-5704Article

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancerROTHENBERG, M. L; ECKARDT, J. R; WEISS, G. R et al.Journal of clinical oncology. 1996, Vol 14, Num 4, pp 1128-1135, issn 0732-183XArticle

The in vitro stability of doxifluridine in whole blood and plasmaSCHAAF, L. J; DOBBS, B. R; EDWARDS, I. R et al.European journal of clinical pharmacology. 1988, Vol 34, Num 5, pp 533-534, issn 0031-6970Article

Influence of smoking and gender on the disposition kinetics of metoprololSCHAAF, L. J; CAMPBELL, S. C; MAYERSOHN, M. B et al.European journal of clinical pharmacology. 1987, Vol 33, Num 4, pp 355-361, issn 0031-6970Article

Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancerDEVORE, R. F; JOHNSON, D. H; MILLER, L. L et al.Journal of clinical oncology. 1999, Vol 17, Num 9, pp 2710-2720, issn 0732-183XArticle

Comparative pharmacology of the novel cyclopropylpyrroloindole-prodrug carzelesin in mice, rats, and humansVAN TELLINGEN, O; NOOIJEN, W. J; SCHAAF, L. J et al.Cancer research (Baltimore). 1998, Vol 58, Num 11, pp 2410-2416, issn 0008-5472Article

Fully automated high-performance liquid chromatographic method for the determination of carzelesin (U-80,244) and metabolites (U-76,073 and U-76,074) in human plasmaVAN TELLINGEN, O; PELS, E. M; HENRAR, R. E. C et al.Journal of chromatography. Biomedical applications. 1994, Vol 652, Num 1, pp 51-58, issn 0378-4347Article

Shelf-lives and factors affecting the stability of morphine sulphate and meperidine (pethidine) hydrochloride in plastic syringes for use in patient-controlled analgesic devicesSTRONG, M. L; SCHAAF, L. J; PANKASKIE, M. C et al.Journal of clinical pharmacy and therapeutics (Print). 1994, Vol 19, Num 6, pp 361-369, issn 0269-4727Article

Comparison of harmonic mean versus arithmetic mean clearance valuesSCHAAF, L. J; LAM, F. C; PERRIER, D. G et al.Journal of pharmaceutical sciences. 1986, Vol 75, Num 4, pp 427-429, issn 0022-3549Article

Analysis of 5'-deoxy-5-fluorouridine and 5-fluorouracil in human plasma and urine by high-performance liquid chromatographySCHAAF, L. J; FERRY, D. G; HUNG, C. T et al.Journal of chromatography. 1985, Vol 342, Num 2, pp 303-313, issn 0021-9673Article